Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
By I. Henderson, D. Berry, G. Demetri, C. Cirrincione, L. Goldstein, S. Martino, J. Ingle, M. Cooper, D. Hayes, K. Tkaczuk and 10 more. Journal of Clinical Oncology, 2003
1,318 citations recorded by the source corpus.
Subfields: Cancer Research, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/3e13d3720c451710696cbd4217772e7358749d8e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- J. Smeds
- P. Hall
- H. Nordgren
- E. Liu
- J. Bergh
- L. Miller
- Y. Pawitan
- A. Ploner
Citations in the corpus
- Triple-negative breast cancer molecular subtyping and treatment progress (2020, background): “Further studies showed that increasing the dose did not improve the survival rate or reduce the relapse rate [30].”
- Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts (2005, background): “The use of anthracyclinebased and taxane-based therapy and more optimal endocrine therapy strategies might alter the distribution of patients, especially moving individuals from type C to type B [37-41], as experienced with the Her-2 status and adjuvant anthracycline therapy [42].”